Good 20light 20  20group jpg
2 20color 20kineta 20logo 20  20new 20tagline

Kineta, Inc.

Kineta rapidly advances leading-edge immunotherapeutic drug candidates through human safety trials, transacts with Pharma, 3 yr. est. to ROI

  • Stage Product In Development
  • Industry Biotechnology
  • Location Seattle, WA, USA
  • Currency USD
  • Founded December 2007
  • Employees 39
  • Incorporation Type C-corp
  • Website

Company Summary

Kineta is a biotech company that fills a void in the pharma industry by advancing therapies from discovery to clinical proof of concept. We work with private, government and industry partners to advance our innovative research. Our unique funding model mitigates risk and may provide an attractive and earlier return for investors. Kineta has established and a pipeline of novel life improving therapies that address critical unmet patient needs.


  • Default avatar
    Shawn Iadonato, PhD
    CEO and Chief Science Officer

    Dr. Iadonato previously co-founded and was CSO of Illumigen Biosciences Inc. where he pioneered the company’s patented drug discovery methodology driven by recruitment and screening of healthy populations. He also led the successful discovery and preclinical development of Illumigen’s anti-HCV drug IB657, which ultimately led to the sale of the company. Earlier he managed the Human Genome Project data collection at the U.W. Genome Center.

  • Default avatar
    Rob Hedequist
    President and COO

    20+ years in the pharmaceutical industry; Corporate development at Kineta; Major Accounts, Managed Care & Sales/ Marketing at Pfizer and Amgen; National Director Schering–Plough

  • Default avatar
    Kristin Bedard
    VP Research & Development

    15+ years of experience in virology and drug development; founding scientist at Kineta; established AViid™ screening platform; 15 US patent applications; awarded 7 NIH grants and contracts

  • A4a8fa1d a26e 4f80 b9be 4235cd5452ce
    SVP Business Development & Corp. Comm.

    20+ years in commercial operations in the pharmaceutical industry; marketing, payer strategy, pricing, national accounts, sales leadership and business development at GSK and Schering-Plough.

  • Default avatar
    Campion Fellin, MSE
    SVP Operations

    25+ years operations and program management experience; Software and Biotech Industries; Manages 10M+ in NIH Grant Awards, IT, accounting, and facilities management expertise.

  • Default avatar
    Pauline Kenny, JD
    General Counsel

    15+ years of legal experience in both in-house and outside counsel roles; general corporate matters, financing, licensing, intellectual property, M&A and other legal and strategic matters

  • Ken 20north 20  20web
    SVP Corporate Development

    39 years of banking and fund raising experience. Corporate Development at Kineta; Founding CEO Seattle Savings Bank; Past president Seattle Kiwanis, Chamber of Commerce, Seafair Commodores

  • E022e9a7 0c1a 4cf6 959c 877d77385997
    VP Translational Development

    15+ years of experience in translational drug development; founding scientist at Kineta; led development for a novel biologic antiviral therapy at Illumigen Biosciences


  • Default avatar
    Moss Adams

Previous Investors

  • Default avatar
    Iacocca Family Foundation
    Default avatar
    Ray and Lydia Bartoszek
    Default avatar